Impact of Upfront DPYD Genotyping on Fluoropyrimidine Adjuvant Therapy in Colorectal Cancer: A Real-World Data
Clinical Colorectal Cancer · 2025
DOI: 10.1016/j.clcc.2025.02.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2025. Verfasst von Jatta Saarenheimo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Wellbeing Services County of Ostrobothnia, Vaasa Central Hospital, Vaasa, Finland; Fimlab Laboratoriot Oy, Patologia, Vaa…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Dihydrouracil Dehydrogenase (NADP), Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Tyks and Hospital District of Southwest Finland.
Abstract (Originalsprache)
BACKGROUND: The application of fluoropyrimidine-based chemotherapy in colorectal cancer treatment is known to pose significant toxicity risks, which can be mitigated by tailoring treatment according to DPYD gene variants. This study evaluates the impact of DPYD genotype-guided dosing on treatment-related toxicities and patient outcomes. METHODS: A retrospective analysis was conducted on CRC patients treated with fluoropyrimidines in adjuvant setting at The Wellbeing Services County of Ostrobothnia. Patients were divided into two cohorts based on the implementation of routine DPYD genotyping: pregenotyping (2016-2018) (n = 80) and postgenotyping (2020-2022) (n = 69). The incidence of side effects, treatment discontinuation, hospitalization, and 90-day mortality were compared between groups. RESULTS: The study revealed a reduction in 90-day mortality rates among patients who underwent DPYD genotyping before treatment. Patients with pathogenic DPYD variants received ≥50% reduced doses initially, leading to no severe toxicities (grade ≥3). Class 3 variants showed similar side effect profiles and hospitalization rates as untested patients but had a lower rate of treatment discontinuation. CONCLUSIONS: Upfront DPYD genotyping appears to improve patient safety in CRC patients treated with adjuvant fluoropyrimidines, leading to personalized dosing that reduces severe toxicities and early mortality. These findings underscore the importance of integrating pharmacogenetic testing in clinical oncology to optimize treatment regimens and enhance patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Wellbeing Services County of Ostrobothnia, Vaasa Central Hospital, Vaasa, Finland; Fimlab Laboratoriot Oy, Patologia, Vaasa, Finland. Electronic address: jatta.saarenheimo@fimlab.fi.
- Department of Oncology, The Wellbeing Services County of Ostrobothnia, Vaasa Central Hospital, Vaasa, Finland; Umeå University, Umeå, Sweden.
- Department of Oncology, The Wellbeing Services County of Ostrobothnia, Vaasa Central Hospital, Vaasa, Finland.
- Department of Oncology, The Wellbeing Services County of Ostrobothnia, Vaasa Central Hospital, Vaasa, Finland; Department of Oncology and Radiotherapy, University of Turku, Turku, Finland.
Förderung
- Tyks and Hospital District of Southwest Finland
Zitieren
APA
Saarenheimo, J., Willför, H., Wahid, N., Jekunen, A., & Andersén, H. (2025). Impact of Upfront DPYD Genotyping on Fluoropyrimidine Adjuvant Therapy in Colorectal Cancer: A Real-World Data. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2025.02.001
Vancouver
Saarenheimo J, Willför H, Wahid N, Jekunen A, Andersén H. Impact of Upfront DPYD Genotyping on Fluoropyrimidine Adjuvant Therapy in Colorectal Cancer: A Real-World Data. Clinical Colorectal Cancer. 2025. doi:10.1016/j.clcc.2025.02.001
BibTeX
@article{Saarenheimo2025,
author = {Saarenheimo, Jatta and Willför, Hugo and Wahid, Nesna and Jekunen, Antti and Andersén, Heidi},
title = {Impact of Upfront DPYD Genotyping on Fluoropyrimidine Adjuvant Therapy in Colorectal Cancer: A Real-World Data},
journal = {Clinical Colorectal Cancer},
year = {2025},
doi = {10.1016/j.clcc.2025.02.001}
}
EUVIMED